Art. -Nr.: HY-N0496

Ruscogenin

7 Cited Publications

Kundenbewertung

Based on 7 publication(s) in Google Scholar

Ruscogenin, an important steroid sapogenin derived from Ophiopogon japonicus, attenuates cerebral ischemia-induced blood-brain barrier dysfunction by suppressing TXNIP/NLRP3 inflammasome activation and the MAPK pathway. Ruscogenin exerts significant anti-inflammatory and anti-thrombotic activities. Ruscogenin has orally bioactivity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.85%
CAS. Nr.: 472-11-7
Formel: C₂₇H₄₂O₄
Molecular Weight:430.62

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Ruscogenin Chemical Structure

CAS. Nr.: 472-11-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (7)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

NLRP3

Alle NOD-like Receptor (NLR) Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
BXPC-3	IC₅₀	7.32 μM Compound: 48	Anticancer activity against human BXPC-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human BXPC-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36332549]
SW1990	IC₅₀	8.14 μM Compound: 48	Anticancer activity against human SW1990 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human SW1990 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36332549]
THP-1	IC₅₀	2.27 μM Compound: 1	Anticoagulant activity in human THP1 cells assessed as inhibition of TNF-alpha-stimulated tissue factor expression incubated 1 hr before TNFalpha challenge measured after 5 hrs Anticoagulant activity in human THP1 cells assessed as inhibition of TNF-alpha-stimulated tissue factor expression incubated 1 hr before TNFalpha challenge measured after 5 hrs	[PMID: 20561785]

In Vitro

Ruscogenin (0.01-40 μM; 24 h) increases the cell viability in bEnd.3 cells subjected to OGD/R^[1].
Ruscogenin (0.01-10 μM; 24 h) reverts the endothelial barrier leakage, inhibits the expression of IL-Iβ and Caspase-1, and modulats the TXNIP/NLRP3 pathway in bEnd.3 cells subjected to OGD/R^[1].
Ruscogenin (0.01-10 μM; 4 h) inhibits the production of ROS, and regulated the MAPK Pathway in bEnd.3 Cells subjected to OGD/R^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

bEnd.3 cell
Concentration:

0.01 μM, 0.1 μM, 1 μM, 10 μM, 20 μM, 40 μM
Incubation Time:

24 h
Result:

Showed that the cell viability reduction in OGD/R-induced bEnd.3 cell was significantly recovered.

Immunofluorescence^[1]

Cell Line:

bEnd.3 cell
Concentration:

0.1 μM, 1 μM, 10 μM
Incubation Time:

24 h
Result:

Demonstrated increase in the TEER value and inhibition the sodium fluorescein permeability.

Western Blot Analysis^[1]

Cell Line:

bEnd.3 cell
Concentration:

0.01 μM, 0.1 μM, 1 μM, 10 μM, 20 μM, 40 μM
Incubation Time:

24 h
Result:

Demonstrated downregulation of the expression of IL-1β and Caspase-1 proteins, and inhibition in the expressions of NLRP3 and TXNIP.

Immunofluorescence^[1]

Cell Line:

bEnd.3 cell
Concentration:

0.01 μM, 0.1 μM, 1 μM, 10 μM, 20 μM, 40 μM
Incubation Time:

4 h
Result:

Demonstrated reduction in the production of ROS.

In Vivo

Ruscogenin (10 mg/kg; i.g.; 1 time) improves the MCAO/R-induced brain tissue injury and inhibits the expression of IL-1β and Caspase-1 and modulats the TXNIP/NLRP3^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

MCAO/R Mice^[1]
Dosage:

10mg/kg
Administration:

Oral Gavage (i.g.)
Result:

Showed smaller infarct size, ameliorating histopathological damage by decreasing the cell loss, and significant increase in CBF (cerebral blood flow) compared to the model group.
Resulted inhibiting the expression of IL-1β and Caspase-1, NLRP3 and TXNIP compared to the model group.

Chemical Information

CAS. Nr. 472-11-7
Appearance Solid
Molecular Weight 430.62
Formel C₂₇H₄₂O₄
Color White to off-white
SMILES

C[C@@]12[C@]([C@@H]3C)([H])[C@](O[C@]34CC[C@@H](C)CO4)([H])C[C@@]1([H])[C@@](CC=C(C[C@@H](O)C5)[C@@]6([C@@H]5O)C)([H])[C@]6([H])CC2
Structure Classification
- Steroids
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (7)

All WBIFFlow CytometryCell Imaging/StainingHistological Imaging/Staining

Sort by:

Journal Impact Factor

Ecotoxicol Environ Saf

Low-dose arsenite causes overexpression of EGF, TGFα, and HSP90 through Trx1-TXNIP-NLRP3 axis mediated signaling pathways in the human bladder epithelial cells. [Abstract]

2022 Dec 1:247:114263. PMID: 36343453
Int Immunopharmacol

Ruscogenin attenuates osteoarthritis by modulating oxidative stress-mediated macrophage reprogramming via directly targeting Sirt3. [Abstract]

2024 Oct 7;143(Pt 1):113336. PMID: 39378655

Ruscogenin purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2024 Oct 7;143(Pt 1):113336. [Abstract]

The CD86, iNOS, and CD206 protein levels in RAW264.7 following LPS and Ruscogenin (RUS) (5, 25 μM) treatment were quantified by western blotting.

Ruscogenin purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2024 Oct 7;143(Pt 1):113336. [Abstract]

Illustrative images of immunofluorescence staining: red ( iNOS/CD206), green (cytoskeleton), and blue (nuclei) following LPS and Ruscogenin (RUS) (5, 25 μM) treatment.

Ruscogenin purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2024 Oct 7;143(Pt 1):113336. [Abstract]

Flow cytometry was used to examine CD86⁺ and CD206⁺ cells following LPS and Ruscogenin (RUS) (5, 25 μM) treatment.

Ruscogenin purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2024 Oct 7;143(Pt 1):113336. [Abstract]

S F and toluidine blue staining of chondrocytes following LPS and Ruscogenin (RUS) (5, 25 μM) treatment.

Ruscogenin purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2024 Oct 7;143(Pt 1):113336. [Abstract]

Illustrative images of S.O and HE staining of ACLT or Ruscogenin (RUS) (5, 10 mg/kg) rat samples at 8 weeks post-surgery.
Sci Rep

HIIT and MICT mitigate endothelial dysfunction in early atherosclerotic mice via PCSK9 inhibition. [Abstract]

2025 Aug 19;15(1):30411. PMID: 40830352
FASEB J

Aberrant DNMTs Promote TXNIP Upregulation and Ovarian Fibrosis in PCOS. [Abstract]

2026 Apr 15;40(7):e71755. PMID: 41934343
Res Sq

2025 Apr 20.
Rev Bras Farm

2025 Apr.
Comput Intell Neurosci

Ruscogenin Prevents Folic Acid-Induced Acute Kidney Damage by Inhibiting Rev-erb α/ β- Mediated Ferroptosis. [Abstract]

2022 Jul 8:2022:8066126. PMID: 35845882

Lösungsmittel & Löslichkeit

In Vitro:

Ethanol : 25 mg/mL (58.06 mM; Need ultrasonic)

DMSO : 4.31 mg/mL (10.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3222 mL

11.6112 mL

23.2223 mL

5 mM

0.4644 mL

2.3222 mL

4.6445 mL

10 mM

0.2322 mL

1.1611 mL

2.3222 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1 mg/mL (2.32 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 1.67 mg/mL (3.88 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Cao G, et al. Ruscogenin Attenuates Cerebral Ischemia-Induced Blood-Brain Barrier Dysfunction by Suppressing TXNIP/NLRP3 Inflammasome Activation and the MAPK Pathway. Int J Mol Sci. 2016 Aug 29;17(9). pii: E1418. [Content Brief]

[2]. Huang YL, et al. Possible mechanism of the anti-inflammatory activity of ruscogenin: role of intercellular adhesion molecule-1 and nuclear factor-kappaB. J Pharmacol Sci. 2008 Oct;108(2):198-205. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / Ethanol	1 mM	2.3222 mL	11.6112 mL	23.2223 mL	58.0558 mL
	5 mM	0.4644 mL	2.3222 mL	4.6445 mL	11.6112 mL
	10 mM	0.2322 mL	1.1611 mL	2.3222 mL	5.8056 mL
Ethanol	15 mM	0.1548 mL	0.7741 mL	1.5482 mL	3.8704 mL
	20 mM	0.1161 mL	0.5806 mL	1.1611 mL	2.9028 mL
	25 mM	0.0929 mL	0.4644 mL	0.9289 mL	2.3222 mL
	30 mM	0.0774 mL	0.3870 mL	0.7741 mL	1.9352 mL
	40 mM	0.0581 mL	0.2903 mL	0.5806 mL	1.4514 mL
	50 mM	0.0464 mL	0.2322 mL	0.4644 mL	1.1611 mL

Keywords

Ruscogenin

7 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Ruscogenin

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Natural Product Library

Antioxidant Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Inflammasomes related Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Cosmetic Ingredient Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Pattern Recognition Receptors Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Ruscogenin

Alle NOD-like Receptor (NLR) Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (7)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Ruscogenin Related Classifications

HY-N0496 Related Classifications